IgA Nephropathy Market - A Global and Regional Analysis

2.1 North America
      2.1.1 Key Findings
      2.1.2 Market Dynamics
      2.1.3 Market Sizing and Forecast
               2.1.3.1 North America IgA Nephropathy Market (by Country)
                           2.1.3.1.1 U.S.
                           2.1.3.1.2 Canada
2.2 Europe
      2.2.1 Key Findings
      2.2.2 Market Dynamics
      2.2.3 Market Sizing and Forecast
               2.2.3.1 Europe IgA Nephropathy Market (by Country)
                           2.2.3.1.1 U.K.
                           2.2.3.1.2 Germany
                           2.2.3.1.3 France
                           2.2.3.1.4 Italy
                           2.2.3.1.5 Spain
                           2.2.3.1.6 Rest-of-Europe
2.3 Asia-Pacific
      2.3.1 Key Findings
      2.3.2 Market Dynamics
      2.3.3 Market Sizing and Forecast
               2.3.3.1 Asia-Pacific IgA Nephropathy Market (by Country)
                           2.3.3.1.1 Japan
                           2.3.3.1.2 China
                           2.3.3.1.3 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
      2.4.1 Key Findings
      2.4.2 Market Dynamics
      2.4.3 Market Sizing and Forecast

3.1 Competitive Landscape
      3.1.1 Key Strategies and Developments by Company
               3.1.1.1 Funding Activities
               3.1.1.2 Mergers and Acquisitions
               3.1.1.3 Regulatory Approvals
               3.1.1.4 Partnerships, Collaborations and Business Expansions
      3.1.2 Key Developments Analysis
3.2 Company Profiles
      3.2.1 Novartis
               3.2.1.1 Company Overview
               3.2.1.2 Product Portfolio
               3.2.1.3 Target Customers/End Users
               3.2.1.4 Analyst View
      3.2.2 F. Hoffmann-La Roche
               3.2.2.1 Company Overview
               3.2.2.2 Product Portfolio
               3.2.2.3 Target Customers/End Users
               3.2.2.4 Analyst View               
      3.2.3 Ionis Pharmaceuticals
               3.2.3.1 Company Overview
               3.2.3.2 Product Portfolio
               3.2.3.3 Target Customers/End Users
               3.2.3.4 Analyst View
      3.2.4 Vertex Pharmaceuticals
               3.2.4.1 Company Overview
               3.2.4.2 Product Portfolio
               3.2.4.3 Target Customers/End Users
               3.2.4.4 Analyst View
      3.2.5 Otsuka Pharmaceutical
               3.2.5.1 Company Overview
               3.2.5.2 Product Portfolio
               3.2.5.3 Target Customers/End Users
               3.2.5.4 Analyst View
      3.2.6 Biogen
               3.2.6.1 Company Overview
               3.2.6.2 Product Portfolio
               3.2.6.3 Target Customers/End Users
               3.2.6.4 Analyst View               
      3.2.7 Arrowhead Pharmaceuticals
               3.2.7.1 Company Overview
               3.2.7.2 Product Portfolio
               3.2.7.3 Target Customers/End Users
               3.2.7.4 Analyst View
      3.2.8 NovelMed
               3.2.8.1 Company Overview
               3.2.8.2 Product Portfolio
               3.2.8.3 Target Customers/End Users
               3.2.8.4 Analyst View
      3.2.9 Q32 Bio
               3.2.9.1 Company Overview
               3.2.9.2 Product Portfolio
               3.2.9.3 Target Customers/End Users
               3.2.9.4 Analyst View
      3.2.10 Takeda Pharmaceutical
               3.2.10.1 Company Overview               
               3.2.10.2 Product Portfolio
               3.2.10.3 Target Customers/End Users               
               3.2.10.4 Analyst View
      3.2.11 Vera Therapeutics
               3.2.11.1 Company Overview
               3.2.11.2 Product Portfolio
               3.2.11.3 Target Customers/End Users
               3.2.11.4 Analyst View
      3.2.12 Biocity Biopharmaceutics Co., Ltd.
               3.2.12.1 Company Overview               
               3.2.12.2 Product Portfolio
               3.2.12.3 Target Customers/End Users               
               3.2.12.4 Analyst View
      3.2.13 Calliditas Therapeutics AB
               3.2.13.1 Company Overview               
               3.2.13.2 Product Portfolio
               3.2.13.3 Target Customers/End Users
               3.2.13.4 Analyst View
      3.2.14 Travere Therapeutics, Inc.
               3.2.14.1 Company Overview               
               3.2.14.2 Product Portfolio
               3.2.14.3 Target Customers/End Users               
               3.2.14.4 Analyst View
      3.2.15 Alexion Pharmaceuticals, Inc.
               3.2.15.1 Company Overview
               3.2.15.2 Product Portfolio
               3.2.15.3 Target Customers/End Users
               3.2.15.4 Analyst View

Table:       Global IgA Nephropathy Market, Regulatory Scenario
Table:       Global IgA Nephropathy Market Dynamics, Impact Analysis

Figure:       Global IgA Nephropathy Market, Market Overview
Figure:       Global IgA Nephropathy Market, Epidemiological Analysis, U.S.
Figure:       Global IgA Nephropathy Market Coverage
Figure:       Global IgA Nephropathy Market Key Trends, Impact Analysis, 2023-2035
Figure:       Global IgA Nephropathy Market, Competitive Landscape, January 2022-April 2025